Rationale Cannabinoid CB1 antagonists/inverse agonists suppress food-motivated behaviors and are being evaluated as potential appetite suppressants. It has been suggested that the effects of CB1 antagonism on food motivation could be related to actions on mesolimbic dopamine (DA). If this were true, then the effects of interference with cannabinoid CB1 transmission should closely resemble the effects of interference with DA transmission. Objective To directly compare the effects of DA antagonists with those of CB1 antagonists/inverse agonists, the present studies employed a concurrent lever-pressing/chow-intake procedure. With this task, interference with DA transmission shifts choice behavior such that lever pressing for a preferred food is decreased but chow intake is increased. Results Rats treated with IP injections of the DA D1 antagonist SCH39166 (ecopipam; 0.05-0.2 mg/kg) or the D2 antagonist eticlopride (0.025-0.1 mg/kg) showed substantial decreases in lever pressing and concomitant increases in chow consumption. In contrast, IP administration of the CB1 neutral antagonist AM4113 (4.0-16.0 mg/kg) or the CB1 antagonist/ inverse agonist AM251 (2.0-8.0 mg/kg) decreased operant responding for pellets, but there was no corresponding increase in chow intake. Conclusions These effects of CB1 antagonists/inverse agonists were similar to those produced by the appetite suppressant fenfluramine and by prefeeding. In contrast, low doses of DA antagonists leave primary food motivation intact, but shift behaviors toward food reinforcers that can be obtained with lower response costs. These results suggest that the effects of interference with CB1 transmission are readily distinguishable from those of reduced DA transmission.
Introduction
Several lines of evidence indicate that cannabinoid systems influence feeding and food-motivated behaviors. CB1 agonists have been shown to elevate levels of food intake (Jamshidi and Taylor 2001; Kirkham et al. 2002; Williams and Kirkham 1999) . Moreover, food intake is impaired by CB1 receptor inverse agonists such as rimonabant (SR141716A), AM251, and AM1387 (Arnone et al. 1997; Colombo et al. 1998; Simiand et al. 1998; Williams and Kirkham 1999; McLaughlin et al. 2003 McLaughlin et al. , 2005 McLaughlin et al. , 2006 PiSunyer et al. 2006; Salamone et al. 2007a) , as well as by neutral CB1 antagonists including AM4113 and O-2050 (Gardner and Mallet 2006; Salamone et al. 2007a; Sink et al. 2007) . Drugs that interfere with CB1 receptor transmission also have been shown to impair food-reinforced behavior (Freedland et al. 2000; McLaughlin et al. 2003 McLaughlin et al. , 2006 Ward and Dykstra 2005; Salamone et al. 2007a; Sink et al. 2007) . Although studies have demonstrated that the suppression of food intake produced by drugs that interfere with CB1 transmission is not related to motor impairments that directly impair ingestion or food handling (McLaughlin et al. 2005 ), the precise mechanisms mediating the effects of CB1 antagonists/inverse agonists on food-related behaviors remain uncertain. Various brain systems have been implicated in the food-related effects of cannabinoid drugs, including the hypothalamus, nucleus accumbens shell, and the parabrachial nucleus (Jamshidi and Taylor 2001; Kirkham et al. 2002; Di Marzo et al. 2001; Di Patrizio and Simansky 2006; Soria-Gomez et al. 2007) . Another suggestion has been that drugs that act on cannabinoid receptors could be modulating dopamine (DA) transmission, particularly in the nucleus accumbens (Cohen et al. 2002; Wenger et al. 2003; Gardner 2005) . CB1 receptor stimulation can increase extracellular DA in nucleus accumbens (Gardner and Lowinson 1991; Tanda et al. 1997; Gardner 2005) , and this effect can be blocked by CB1 receptor antagonism (Tanda et al. 1997) . Recent evidence indicates that the CB1 receptor antagonist/inverse agonist rimonabant can reduce the increase in extracellular DA in nucleus accumbens that accompanies consumption of a palatable food (Melis et al. 2007) , and it has been suggested that interference with CB1 receptor transmission could reduce feeding by reducing mesolimbic DA activity (Melis et al. 2007) .
Nevertheless, there appear to be some difficulties with the idea that drugs that interfere with CB1 transmission act on food-motivated behaviors by decreasing activity of DA systems that are hypothesized to mediate primary food motivation. There is considerable evidence demonstrating that the mesolimbic DA system does not mediate primary food "reward," motivation, or appetite (Salamone et al. 1997 (Salamone et al. , 2007b Salamone and Correa 2002; Kelley et al. 2005) . Several studies have shown that nucleus accumbens DA depletion or antagonism does not suppress food intake (Ungerstedt 1971; Koob et al. 1978; Salamone et al. 1993; Baldo et al. 2002) ; thus, it does not seem highly likely that CB1 antagonists decrease food intake because they reduce accumbens DA release. In addition, there are very few studies that have offered direct comparisons between the behavioral effects of DA and CB1 antagonists. It is reasonable to suggest that, if CB1 antagonists or inverse agonists are exerting their effects on food motivation by reducing DA transmission, then the effects of these CB1-related drugs should closely resemble the effects of DA antagonists. The present studies were undertaken to assess this possibility. These experiments employed a concurrent lever-pressing/chow-feeding procedure that has been used to assess the effects of DA manipulations (Salamone et al. 1991 (Salamone et al. , 1997 (Salamone et al. , 2007b Cousins et al. 1993; Nowend et al. 2001; Farrar et al. 2007) . With this procedure, rats can press a lever to receive a preferred food (Bioserv pellets) or, alternatively, they may approach and consume less-preferred lab chow that is concurrently available in the operant chamber (Salamone et al. 1991 (Salamone et al. , 1997 Cousins et al. 1993 Nowend et al. 2001; Farrar et al. 2007 ). Under baseline conditions, rats pressing on a fixed-ratio 5 (FR5) schedule typically obtain most of their food by pressing the lever, consuming very little of the laboratory chow. In rats performing this task, prefeeding to reduce food motivation was shown to suppress both lever pressing and chow intake (Salamone et al. 1991) . In contrast, low-to-moderate doses of DA antagonists, injected systemically or directly into the accumbens, produced a very different pattern of effects. Systemic injections of DA antagonists with varying selectivity profiles, including cis-flupenthixol, haloperidol, raclopride, SCH23390, and SKF83566, all decreased lever pressing for food but substantially increased intake of the concurrently available chow (Salamone et al. 1991 Koch et al. 2000) . The low dose of haloperidol that produced this shift in behavior (0.1 mg/kg) did not alter intake of the preferred or nonpreferred foods, nor did DA antagonism change food preferences in free-feeding choice tests (Salamone et al. 1991) . The shift from lever pressing to chow intake that is produced by systemic DA antagonists was induced by accumbens DA depletions and intraaccumbens injections of DA antagonists into core or shell regions (Salamone et al. 1991; Cousins et al. 1993; Sokolowski and Salamone 1998; Koch et al. 2000; Nowend et al. 2001 ).
The present experiments were designed to study the effects of systemic injections of CB1 antagonists and inverse agonists on performance of the concurrent choice task, and to compare the actions of these drugs against those of highly selective D1-and D2-family DA antagonists. AM251 is a CB1 antagonist/inverse agonist that has been shown to suppress food intake and food-reinforced operant responding (McLaughlin et al. 2003 (McLaughlin et al. , 2005 . AM4113 is a novel CB1 receptor neutral antagonist. It was recently reported that this drug effectively reduces feeding and food-motivated behaviors similarly to AM251, but unlike AM251, AM4113 did not induce behaviors associated with nausea and malaise (Sink et al. 2007 ). Neither of these compounds has been evaluated for their effects on the concurrent lever-pressing/chow-intake choice procedure. For comparison purposes, two DA antagonists that have not previously been assessed for their effects in the concurrent choice task were studied as well. Previous work has shown that D1-family antagonists SCH23390 Nowend et al. 2001 ) and SKF83566 decrease lever pressing and increase chow consumption on the concurrent choice task. To broaden the pharmacological knowledge in this area, and provide direct comparisons with the effects of AM251 and AM4113, the D1-family antagonist SCH39166 (ecopipam) was studied in the present work. SCH39166 binds to D1 receptors with high affinity, but unlike SCH23390, SCH39166 binds to 5HT2 A and 5HT2 C receptors with a very low affinity (Alburges et al. 1992) . Previous studies employing the concurrent choice task have examined the effects of haloperidol and raclopride (Salamone et al. 1991 , and thus, for the present work, the potent and selective D2-family antagonist eticlopride was investigated. Because interference with CB1 transmission is thought to decrease appetite or produce food aversions (McLaughlin et al. 2005; Sink et al. 2007) , it was hypothesized that the CB1 antagonist and inverse agonist drugs would both suppress lever pressing but would fail to increase chow intake. In contrast, it was expected that both DA antagonists would produce a reallocation of behavior resulting in reduced lever pressing and increased chow intake.
Materials and methods

Animals
Adult male Sprague-Dawley rats (Harlan Sprague-Dawley, Indianapolis, IN, USA) weighing at least 300 g at the beginning of the experiments were housed in a colony maintained at 23°C, with a 12-h light/dark cycle (lights on 07:00). Rats (total N=34) were food-deprived to 85% of their free-feeding body weight for initial operant training and were allowed modest weight growth (i.e., an additional 5-10%) during the experiment. Water was available ad libitum in the home cages. Animal protocols were approved by the University of Connecticut Institutional Animal Care and Use Committee, and the studies were conducted according to NIH guidelines for animal care and use.
Behavioral procedures
Behavioral sessions were conducted in operant conditioning chambers (28×23×23 cm; Med Associates, St. Albans, VT, USA). Animals were initially trained to lever-press for 4 days (30-min sessions; 45-mg pellets, Bioserve, Frenchtown, NJ, USA, were used for all operant behavior tests) and then were changed to an FR5 schedule (30-min sessions, 5 days/week) and trained for several weeks. Rats were then trained on the concurrent FR5/chow-feeding procedure following the initial FR5 training. For this procedure, weighed amounts of lab chow (LC, Prolab 3000 LabDiet, Purina Mills, St. Louis, MO, USA; typically 15-20 g, three large pieces) were concurrently available on the floor of the chamber during the FR5 sessions. At the end of the session, rats were immediately removed from the chamber. Food intake was determined by weighing the remaining food, including spillage. Rats were trained until achievement of stable baseline levels of chow intake and lever pressing (i.e., consistent responding over 1,200 lever presses per 30 min) before any drug testing began.
Pharmacological agents AM251 and AM4113 (synthesized in the Makriyannis Laboratory) were dissolved in a vehicle of dimethylsulfoxide (DMSO; Fisher, Waltham, MA, USA), Tween-80 (Fisher), and 0.9% saline in a 1:1:8 ratio. This mixture also served as the vehicle control treatment in experiments 1 and 2. Doses and pretreatment times for AM251 and AM4113 were chosen based upon pilot studies and previously published research (McLaughlin et al. 2003; Sink et al. 2007 ). They were selected to produce a suppression of lever pressing that was comparable to that produced by the DA antagonists. SCH39166 (ecopipam; (6aS-trans)-11-Chloro-6,6a,7,8,9, 13b-hexahydro-7-methyl-5H-benzo[d] aphtha[2,1-b]azepin-12-ol hydrobromide), obtained from Tocris Bioscience (Ellisville, MO, USA), was dissolved in a 0.3% tartaric acid solution (pH=4.0), which was also used as the vehicle control condition for experiment 3. Eticlopride (S(−)-3-Chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide hydrochloride) was obtained from Sigma Chemical (St. Louis, MO, USA) and was dissolved in a 0.9% saline solution, which was also used as the vehicle control condition for experiment 4. SCH39166 and eticlopride doses and pretreatment times were selected based upon pilot studies. For all experiments, drug or vehicle were administered IP (see descriptions of individual experiments for drug administration schedule).
Experimental procedures
The rats were thoroughly trained on the concurrent FR5/ chow-feeding procedure (see above) before drug testing began, and different groups of rats were used for each experiment. All experiments used a within-groups design, with all rats receiving all IP drug treatments in their particular experiment in a randomly varied order (one treatment per week; no treatment sequences were repeated across different animals in the same experiment). Baseline training (i.e., nondrug) sessions were conducted four additional days per week. The following treatments and testing times were used for each experiment: Experiment 1. AM251: 1.0 ml/kg vehicle, 2.0, 4.0, and 8.0 mg/kg AM251 IP (30 min before testing; n=9) 
Statistical analyses
Total number of lever presses and gram quantity of chow intake in the concurrent choice experiments were analyzed with repeated measures analysis of variance (ANOVA). When the overall ANOVA was significant, nonorthogonal planned comparisons using the overall error term were used to compare each treatment with the vehicle control. The alpha level for each comparison was kept at 0.05 because the number of comparisons was restricted to the number of treatments minus one (Keppel 1982) . In addition, correlational analyses were used to measure the relation between lever pressing and chow consumption for each drug study, with the data collapsed across injection treatments within each study.
Results
Experiments 1 and 2: effects of AM251 and AM4113 on the concurrent FR5/chow-feeding procedure
The results of experiment 1 are shown in Fig. 1 . There was an overall significant effect of AM251 treatment on leverpressing [ Fig. 1a ; F(3,24)=14.1, p<0.001]. Planned comparisons showed that AM251 produced a significant reduction in lever pressing compared to vehicle control for all doses (p<0.05). There was no overall significant effect on chow consumption [ Fig. 1b ; F(3,24)=1.118, p= 0.361], although linear regression analysis suggested that there was a tendency for levels of chow intake to decrease as a function of dose [F(1,34)=3.48, p=0.07]. In addition, six of nine rats showed lower levels of chow intake at the high dose of AM251 compared to vehicle. The results of experiment 2 (AM4113) are shown in Fig. 2 . There was an overall significant effect of drug treatment on lever-pressing [ Fig. 2a ; F(3,18)=21.488, p<0.001]. Planned comparisons showed that AM4113 produced a significant reduction in lever pressing compared to vehicle control for all doses (p< 0.05). Neither the overall ANOVA nor regression analyses demonstrated dose-related changes in chow consumption (Fig. 2b) . Nevertheless, five of seven rats showed lower levels of chow intake after treatment with the high dose of AM4113 compared to vehicle.
Experiments 3 and 4: effects of SCH39166 and eticlopride on the concurrent FR5/chow-feeding procedure
The results of experiment 3 are summarized in Fig. 3 . SCH39166 produced a significant decrease in lever pressing [F(3,21)=19.943, p<0.001; Fig. 3a] and, at the same time, significantly increased chow consumption [F(3,21)=6.821, p=0.002; Fig. 3b ]. Planned comparisons showed that SCH39166 significantly reduced lever pressing at all doses compared to vehicle and increased chow consumption compared to vehicle control at doses of 0.1 and 0.2 mg/kg (p<0.05). Figure 4 shows the results of experiment 4. Eticlopride produced a significant decrease in lever pressing [F(3,27) =22.57, p<0.001; Fig. 4a ] and also significantly increased chow intake [F(3,27)=14.780, p<0.001; 
Correlational analyses across experiments 1-5
One of the statistical markers that has been used in previous experiments to characterize the shift from lever pressing to chow intake induced by DA antagonism has been the presence or absence of an inverse correlation between these two variables. For these analyses, data within each experiment were collapsed across all treatment conditions. In the first two experiments, data from rats treated with either AM251 or AM4113 failed to show a significant relation between lever pressing and chow intake (AM251: r=−0.057, NS; AM4113: r=0.070, NS). In contrast, a significant and robust inverse correlation was observed with the DA antagonists (SCH39166: r=−0.798, df=30, p< 0.001; eticlopride: r=−0.649, df=38, p<0.001).
Discussion
In the studies described above, a concurrent lever-pressing/ feeding task was used to compare the effects of drugs that interfere with cannabinoid CB1 transmission with those of drugs that act as DA antagonists. These experiments were undertaken to determine if CB1 antagonists/inverse agonists could produce effects on food-motivated behavior that closely resemble those produced by DA antagonists. The DA antagonists SCH39166 and eticlopride both showed similar effects, i.e., there was a shift from lever pressing to chow intake, such that drug-induced decreases in lever pressing were accompanied by increases in chow intake. In contrast, the cannabinoid antagonist/inverse agonist AM251 and the CB1 neutral antagonist AM4113 failed to increase chow intake at doses that suppressed food-reinforced lever pressing. Although lever pressing and chow intake showed a robust inverse correlation in rats treated with DA antagonists, these variables were unrelated in rats treated with the drugs that impaired cannabinoid CB1 transmission. Overall, these data indicate that CB1 antagonists/inverse agonists and DA antagonists produce different types of behavioral effects, which seems to argue against the idea that interference with CB1 transmission suppresses foodmotivated behavior because of actions mediated by reductions in DA transmission. Experiments 1 and 2 demonstrated that the CB1 antagonist/inverse agonist AM251 and the neutral CB1 antagonist AM4113 both decreased food-reinforced lever pressing. These data are consistent with previous studies showing that interference with cannabinoid CB1 transmission can suppress food-reinforced instrumental behavior (Freedland et al. 2000; McLaughlin et al. 2003 McLaughlin et al. , 2006 Ward and Dykstra 2005; Salamone et al. 2007a; Sink et al. 2007 ). However, these earlier studies were conducted using conventional operant schedules. In the present work, rats were tested on a concurrent choice procedure, in which a less-preferred food (lab chow) was also available in the chamber. The dose ranges of AM251 and AM4113 that were tested produced a wide variation in operant response suppression (i.e., approximately 30-87.5% reductions), matching the effects produced by DA antagonists. Nevertheless, the decreases in lever pressing produced by AM251 and AM4113 were not accompanied by any increases in chow intake. In fact, there was a slight tendency for AM251 and AM4113 to decrease chow intake as dose increased, although a floor effect due to low baseline levels of chow intake probably prevented a significant effect from being observed in the present study. Previous papers that assessed chow intake separately showed that the doses of AM251 and AM4113 used in the present study also suppressed chow intake (McLaughlin et al. 2003; Sink et al. 2007 ). The present results with AM251 and AM4113 are similar to those reported previously for other manipulations that are thought to affect aspects of appetite. In earlier work employing the concurrent choice task, prefeeding to reduce food motivation and administration of appetite suppressants such as amphetamine and fenfluramine all failed to increase chow intake under conditions that suppressed foodreinforced lever pressing (Salamone et al. 1991 . Thus, although the effects of cannabinoid CB1 receptor antagonists/inverse agonists on performance of the concurrent choice task differed markedly from those produced by DA antagonists (see detailed discussion below), they were similar to those produced by other manipulations that are known to suppress appetite. Taken together, these results suggest that interference with CB1 transmission suppresses food-reinforced behavior because of broad effects on directional aspects of primary food motivation (i.e., processes directing behavior towards consumption of food). The precise mechanisms underlying these effects are unknown. Several papers have concluded that CB1 inverse agonists may act to suppress appetite (Arnone et al. 1997; Colombo et al. 1998; Simiand et al. 1998; McLaughlin et al. 2003 McLaughlin et al. , 2005 McLaughlin et al. , 2006 ; see review by Salamone et al. 2007a) . It has been suggested that competition from other responses (e.g., grooming, scratching) could contribute to the decreases in feeding produced by rimonabant (Tallett et al. 2007) , and it has also been reported that CB1 inverse agonists can produce food aversions (McLaughlin et al. 2005; Salamone et al. 2007a ; but see also Thornton-Jones et al. 2005) . A recent study has demonstrated that the neutral antagonist, AM4113, suppressed food intake at doses that did not induce conditioned gaping, which is a sign of nausea in rats (Sink et al. 2007 ). Yet, regardless of the particular mechanism involved, it does appear that interference with CB1 transmission suppresses food-motivated instrumental behavior because of direct actions on food intake regulation mechanisms.
The results seen after administration of DA antagonists differed markedly from those produced by AM251 and AM4113. Consistent with a large body of data, the D1-family antagonist SCH31966 and the D2-family antagonist eticlopride both produced a shift in behavior on the choice task, i.e., drug-induced decreases in lever pressing were accompanied by increases in chow intake. Previous work has shown that systemic injections of DA antagonists with varying selectivity profiles, including nonselective and D1-and D2-family selective drugs, all decreased lever pressing for food but substantially increased consumption of the concurrently available chow (Salamone et al. 1991 Koch et al. 2000) . Although D1-and D2-family antagonists have been reported to have different effects on several behaviors, including meal patterning (Clifton et al. 1991; Clifton 1995) , they produce similar effects on response allocation as measured by the concurrent lever-pressing/feeding task. In the present studies, as well as in previous work (Cousins et al. 1993; Sokolowski and Salamone 1998; , there was a robust inverse correlation between lever pressing and chow intake in rats treated with DA D1-and D2-family antagonists. This correlation was not seen in animals treated with AM251 or AM4113 (experiments 1-2), nor was it previously observed in rats treated with the appetite suppressant fenfluramine . The shift in behavior from lever pressing to chow intake that is seen after systemic DA antagonism is not seen after local depletions of DA in anterior or ventrolateral neostriatum (Cousins et al. 1993 ), but it is observed after local DA depletion or antagonism in the nucleus accumbens (Salamone et al. 1991; Cousins et al. 1993; Sokolowski and Salamone 1998; Koch et al. 2000; Nowend et al. 2001 ). Thus, rats that have been injected with low doses of DA antagonists, as well as those that have accumbens DA depletions, remain directed towards the acquisition and consumption of food despite their diminished level of lever pressing. These data have been interpreted as indicating that DA is involved in activational aspects of motivation (e.g., increased activity, exertion of effort, overcoming response costs) and response allocation in effort-related choice tasks, but that fundamental aspects of primary food motivation and appetite are left intact after low doses of DA antagonists or interference with accumbens DA transmission (Salamone et al. 1991 (Salamone et al. , 1997 (Salamone et al. , 2007b Aberman et al. 1998; Aberman and Salamone 1999; Kelley et al. 2005; Baldo and Kelley 2007) . This observation is consistent with several previous studies. In separate food intake tests, low doses of DA antagonists that reduced lever pressing did not suppress chow intake (Rolls et al. 1974; Fibiger et al. 1976; Rusk and Cooper 1994) or intake of Bioserve pellets (Salamone et al. 1991) . Similar findings have been reported for water-reinforced responding (Ljungberg 1987 (Ljungberg , 1988 (Ljungberg , 1990 . Previous studies showed that a 0.1-mg/kg dose of haloperidol did not suppress chow intake or reduce time spent feeding on chow (Salamone et al. 1990) , although this dose has been shown consistently to suppress lever pressing and increase chow intake in the concurrent choice task (Salamone 1986; Salamone et al. 1991 Salamone et al. , 1996 Farrar et al. 2007 ). Clifton et al. (1991) reported that low doses of the D1 antagonist SCH23390 had little effect on food intake and that low doses of the D2 antagonists raclopride and YM-09151-2 actually increased meal duration and size. A number of studies have demonstrated that fundamental aspects of food motivation, including perception and discrimination of food reward magnitude, and appetitive taste reactivity to food, are left intact after DA antagonists or accumbens DA depletions (Martin-Iverson et al. 1987; Salamone et al. 1990 Salamone et al. , 1994 Treit and Berridge 1990; Cousins et al. 1996; Aparicio 1998; Berridge and Robinson 1998; Berridge 2000 ; for reviews, see Salamone et al. 1997 Salamone et al. , 1999 Salamone et al. , 2003 Salamone et al. , 2005 Salamone et al. , 2006 Salamone et al. , 2007b . Injections of D1-or D2-family antagonists into either the core or shell subregions of nucleus accumbens, in doses that suppressed locomotion, failed to suppress food intake (Baldo et al. 2002) . Taking all these findings together with the present data, it would be extremely difficult to argue that low doses of DA antagonists, or accumbens DA depletions, suppress food-reinforced lever pressing because of a reduction in appetite or a general loss of food motivation (Salamone et al. 1991 (Salamone et al. , 1997 (Salamone et al. , 2007b Panksepp 1996, 1999; Kelley et al. 2005) . Nevertheless, as discussed above, this does appear to be a reasonable explanation for the effects of CB1 antagonists and inverse agonists on food-reinforced behavior.
Other studies have reported that interference with cannabinoid CB1 receptor function produces behavioral effects that are different from those produced by DA antagonism or DA depletion. For example, food consumption can be suppressed by high doses of DA antagonists (e.g., 0.2 mg/kg or greater) and whole neostriatal DA depletions, and a major parameter of food intake that is affected by these conditions is the rate of feeding (i.e., grams intake per minute spent eating; Blundell 1987; Salamone et al. 1990 Salamone et al. , 1993 . Although nucleus accumbens DA depletions have little effect on food intake (Koob et al. 1978; Salamone et al. 1993) , local depletions of DA in the ventrolateral neostriatum impaired food intake primarily by reducing feeding rate and disrupting forepaw used during food handling, with little effect on time spent feeding . In contrast, doses of AM251 that impaired food intake had substantial effects on time spent feeding but did not significantly affect feeding rate or food handling (McLaughlin et al. 2005) . Taken together, detailed analyses conducted across different types of behavioral tests (i.e., response allocation in effort-related choice, food intake) seem to suggest that, although interference with DA and CB1 receptor function can affect aspects of food-related behavior, the specific patterns of effects produced by each class of drugs (i.e., DA antagonists and CB1 antagonists/ inverse agonists) are quite distinct from each other. Thus, despite results indicating that modulation of CB1 receptors can alter aspects of DA transmission (Gardner 2005; Melis et al. 2007 ), it does not appear that CB1 antagonists or inverse agonists are exerting their effects on food-motivated behavior in a manner that is directly mediated via reduced DA transmission in nucleus accumbens.
